| Literature DB >> 27887595 |
Xudong Ma1, Jianfeng Xie2, Yi Yang2, Fengmei Guo2, Zhiwei Gao2, Hua Shao3, Yingzi Huang2, Congshan Yang2, Haibo Qiu4.
Abstract
BACKGROUND: China's Ministry of Health (MOH) has established a policy about the antimicrobial stewardship. To date, the effects of this policy on multidrug-resistant organism (MDRO) in critically ill patients are unknown.Entities:
Keywords: Antimicrobial consumption; Antimicrobial stewardship; Defined daily dose; Multidrug-resistant organism
Mesh:
Substances:
Year: 2016 PMID: 27887595 PMCID: PMC5123232 DOI: 10.1186/s12879-016-2051-8
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Summary of patient characteristics
| All patients (978) | Before management (433) | After Management (545) |
| |
|---|---|---|---|---|
| Age, years | 64 ± 19 | 64 ± 19 | 65 ± 18 | 0.319 |
| Male (%) | 630 (64) | 267 (62) | 363 (67) | 0.109 |
| APACHEII score | 16 ± 9 | 16 ± 9 | 16 ± 9 | 0.578 |
| Admission source | ||||
| Emergency | 313 (32) | 132 (30) | 181 (33) | 0.268 |
| Surgery | 473 (48) | 205 (47) | 268 (49) | 0.569 |
| Medicine | 192 (20) | 96 (22) | 96 (18) | 0.075 |
| ICU mortality (%) | 244 (25) | 112 (26) | 132 (24) | 0.55 |
| Hospital mortality (%) | 281 (29) | 133 (31) | 148 (27) | 0.22 |
| Duration of ICU stay | 5 (2–10) | 5 (2–10) | 5 (2–10) | 0.954 |
| Duration of hospitalization | 17 (8–30) | 18 (8–33) | 17 (9–30) | 0.009 |
APACHEII Acute Physiology and Chronic Health Evaluation II
Fig. 1Antibiotic consumption of our hospital and ICU decreased after the management of antibacterial drugs in clinical applications
Mean monthly DDD per 100 occupied bed-days before and after the antimicrobial stewardship
| Department | Before management | After management |
|
|---|---|---|---|
| All | 96 ± 7 | 65 ± 6 | <0.001 |
| Neurosurgery | 78 ± 26 | 45 ± 17 | 0.002 |
| Thoracic surgery | 96 ± 20 | 106 ± 36 | 0.38 |
| General surgery | 115 ± 16 | 93 + 20 | 0.003 |
| Urology surgery | 117 ± 15 | 129 ± 10 | 0.02 |
| Orthopedics | 82 ± 9 | 40 + 7 | <0.001 |
| Respiratory medicine | 178 ± 18 | 128 + 15 | <0.001 |
| Neurology | 36 ± 9 | 35 ± 12 | 0.963 |
| Cardiology | 74 ± 12 | 35 ± 6 | <0.001 |
| ICU | 170 ± 28 | 159 ± 44 | 0.018 |
Fig. 2Proportion of patient colonization of infection with MDRO at the time of ICU admission and discharge decreased after antimicrobial clinical application management
Proportion of patients colonized or infected with MDRO before and after antimicrobial stewardship
| Department | All patients (978) | Before management (433) | After management (545) |
|
|---|---|---|---|---|
| All, n (%) | 225 (23.01) | 154 (35.57) | 71 (13.03) | <0.001 |
| Emergency, n (%) | 86 (23.76) | 54 (40.91) | 32 (17.68) | <0.001 |
| Surgery, n (%) | 91 (19.24) | 68 (33.17) | 23 (8.58) | <0.001 |
| Neurosurgery, n (%) | 11 (13.75) | 5 (29.41) | 6 (9.52) | 0.035 |
| Thoracic surgery, n (%) | 12 (10.52) | 11 (20.37) | 1 (1.67) | 0.001 |
| General surgery, n (%) | 35 (26.92) | 28 (40.00) | 7 (11.67) | <0.001 |
| Urology surgery, n (%) | 10 (28.57) | 8 (38.10) | 2 (14.29) | 0.252 |
| Orthopedics, n (%) | 8 (18.18) | 8 (40.00) | 0 (0) | 0.001 |
| Other, n (%) | 13 (18.57) | 6 (26.09) | 7 (14.89) | 0.258 |
| Medicine, n (%) | 50 (27.47) | 34 (30.52) | 16 (16.84) | 0.033 |
| Respiratory medicine, n (%) | 10 (32.26) | 8 (50.00) | 2 (13.33) | 0.054 |
| Neurology, n (%) | 13 (38.23) | 8 (42.11) | 5 (33.33) | 0.728 |
| Cardiology, n (%) | 7 (15.22) | 5 (21.73) | 2 (8.70) | 0.218 |
| Other, n (%) | 20 (25.00) | 13 (35.14) | 7 (16.28) | 0.062 |
Microorganisms isolation at the time of ICU admission and discharge
| ICU admission | ICU discharge | |
|---|---|---|
| All microorganisms | 1054 (100) | 1040 (100) |
| Multidrug-resistant bacteriaa | 273 (25.9) | 369 (35.5) |
| Methicillin-resistant | 75 (27.4) | 74 (20.1) |
| Vancomycin-resistant enterococcib | 10 (3.6) | 8 (2.2) |
|
| 12 (4.4) | 18 (4.9) |
|
| 83 (30.4) | 150 (40.7) |
|
| 24 (8.8) | 27 (7.3) |
|
| 15 (5.5) | 24 (6.5) |
|
| 5 (1.8) | 3 (0.5) |
|
| 1 (0.4) | 4 (1.1) |
| Otherb | 46 (16.8) | 59 (16.0) |
| Non-multidrug-resistant bacteriaa | 781 (74.1) | 671 (64.5) |
|
| 375 (45.7) | 307 (45.8) |
|
| 33 (4.2) | 32 (4.8) |
| Methicillin-sensitive S | 49 (6.3) | 51 (7.6) |
|
| 18 (2.6) | 21 (3.1) |
|
| 15 (1.9) | 13 (1.9) |
|
| 10 (1.3) | 11 (1.6) |
|
| 26 (3.3) | 20 (3.0) |
|
| 100 (12.8) | 84 (12.5) |
|
| 13 (1.7) | 12 (1.8) |
|
| 7 (0.9) | 6 (0.9) |
| Othersc | 140 (17.9) | 111 (16.5) |
Data were presented by counts and percentage
aPercentage equals the counts of the item divided by all microorganisms
bPercentage equals the counts of the item divided by multidrug-resistant bacteria
cPercentage equals the counts of the item divided by non-multidrug-resistant bacteria
ICU intensive care unit
Fig. 3A significant positive relationship between the proportion of critically ill patient colonization or infection with MDRO at the time of ICU admission monthly and total antimicrobial consumption in our hospital monthly (R2 = 0.7858, p < 0.001)
Fig. 4a There was no relationship between the DDD in the ICU and the MDRO rate at the time of ICU discharge (R2 = 0.1085, p = 0.116); b there was significant relationship between increased percentage of MDRO rate from the time of ICU admission to discharge from the ICU and DDD in the ICU (R2 = 0.2056, p = 0.038)
Fig. 5a There was no significant relationship between carbapenem consumption throughout the hospital and resistance of A. baumannii to carbapenem at the time of ICU admission (R2 = 0.0436, p = 0.393). b There was no significant relationship between carbapenem consumption in the ICU and resistance of A. baumannii to carbapenem at the time of ICU discharge (R2 = 0.0798, p = 0.181)